MCK · 10-Q · 2026Q2 · Full report

Products and Technology

MCKESSON CORP · 2026-08-05 · Importance 10 · Surprise 6 · Matches filing data

McKesson provides branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical distribution and logistics, along with financial, operational, clinical, consulting, outsourcing, and technology solutions for pharmacies. Prescription Technology Solutions connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address medication access, affordability, and adherence. Its offerings include electronic prior authorization, prescription price transparency, benefit insight, dispensing support, patient enrollment, and third-party logistics across therapeutic categories and temperature ranges. Medical-Surgical Solutions offers national-brand medical-surgical products and more than 4,000 company-branded products to non-acute healthcare providers.

Key facts

• Estimated amortization expense thereafter: $2,710 million (line item 'Thereafter 2,710') source
• As of June 30, 2026 goodwill by segment: North American Pharmaceutical $2,755 million; Oncology & Multispecialty $3,951 million; Prescription Technology Solutions $2,065 million; Medical-Surgical Solutions $2,507 million; Total goodwill $11,278 million source
• Intangible assets gross carrying amount at June 30, 2026: $6,067 million; accumulated amortization $2,054 million; net carrying amount $4,013 million source
• Segment reporting structure implemented in Q2 fiscal 2026 resulted in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, with former Norwegian operations included in Other. source
• Segment operating profit margin for Prescription Technology Solutions for the three months ended June 30, 2026: 14.43%; for the three months ended June 30, 2025: 17.64%. source
• Prescription Technology Solutions revenues increased $132 million or 9% for the three months ended June 30, 2026 compared to the same prior year period primarily due to increased volumes from third-party logistics. source
• Operating profit for Prescription Technology Solutions decreased for the three months ended June 30, 2026 driven by higher restructuring charges and increased operating expenses to support higher volumes, partially offset by increased demand for Access Solutions. source
• Prescription Technology Solutions segment revenues for the three months ended June 30, 2026: $1,566 million; for the three months ended June 30, 2025: $1,434 million. source

Impact estimates